Announcement • Sep 27

China Traditional Chinese Medicine Holdings Co. Limited Announces Executive, Board and Committee Appointments

The board of directors of China Traditional Chinese Medicine Holdings Co. Limited announced that the Board resolved on 27 September 2024 that due to change of his work arrangement, Mr. CHEN Yinglong ceased to serve as the executive Director and chairman of the Board with immediate effect. Mr. CHEN has also ceased to serve as chairman of each of the nomination committee and the strategic committee of the Board upon his resignation as an executive Director, and ceased to be the acting president (i.e. the general manager). The Board hereby announces that Mr. YANG Jun and Mr. LI Hongjian have been appointed as executive Directors, with effect from 27 September 2024. Mr. YANG and Mr. LI will individually enter into an employment agreement with the Company in relation to their appointments with effect from 27 September 2024, which shall automatically be effective hereafter. They shall hold office only until the first annual general meeting of the Company after their appointments and shall then be eligible for re-election. Thereafter, Mr. YANG and Mr. LI are subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The aggregate remuneration of Mr. YANG and Mr. LI will be determined by the remuneration and evaluation committee of the Board in accordance with reference to their duties, market rate and their time, effort, expertise and responsibilities to be exercised on the Group's affairs and with the Company's remuneration policy. Currently, according to the Company's remuneration policy, Mr. YANG and Mr. LI will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement. The Board hereby announces that Mr. LI has been appointed as the president (i.e. the general manager) of the Company, with effect from 27 September 2024. The Board hereby announces that Mr. YANG has been appointed as the chairman of each of the Nomination Committee and the Strategic Committee and Mr. LI as a member of each of the Nomination Committee and the Strategic Committee, Mr. YANG Binghua, a non-executive Director, has been appointed as a member of the Nomination Committee, and Mr. CHENG Xueren and Mr. YANG Wenming, both as non-executive Directors, have ceased to serve as members of the Nomination Committee, with effect from 27 September 2024. The Board further announces that Mr. CHEN has ceased to act as an authorised representative of the Company (the "Authorised Representative") under Rule 3.05 of the Listing Rules following his resignation, and Mr. YANG has been appointed as the Authorised Representative with effect from 27 September 2024. Mr. YANG Jun, aged 58, has been appointed to the Board since 27 September 2024. The Board hereby announces that Mr. LI has been appointed as the president (i.e. the general manager) of the Company, with effect from 27 September 2024. Mr. YANG graduated from Beijing Normal University with a bachelor degree majoring in education management in July 1989, and completed study in economic management in the in-service postgraduate class of the Graduate School of The Party School of the Communist Party of China Central Committee in July 2001. Mr. YANG has a senior marketing qualification certificate. Mr. YANG successively served as a secretary of the office, deputy director of the supply and marketing department, manager of the comprehensive planning department, deputy manager of the preparation department, traditional Chinese medicine department (concurrently) and the operating business headquarters of China Pharmaceutical Industry Corporation from July 1989 to May 2005; served as municipal marketing director and hospital manager (concurrently) of China Pharmaceutical Industry Company Limited from May 2005 to June 2006; successively served as deputy director and director of the operation management department and director of the international cooperation department of China National Pharmaceutical Group Corporation () (currently known as China National Pharmaceutical Group Co. Ltd.) from June 2006 to March 2014; served as the secretary of the discipline inspection commission of Sinopharm Group Co. Ltd. (listed on the Stock Exchange, stock code: 01099) from March 2014 to January 2018; served as the president, deputy secretary of the Party Committee and a director of Shyndec Pharmaceutical Co. Ltd. (listed on the Shanghai Stock Exchange, stock code: 600420) from January 2018 to July 2020; served as deputy secretary of the Party Committee (chief) of China Sinopharm International Corporation from July 2020 to June 2022; successively served as the secretary of the Party Committee, deputy general manager and chairman (legal representative) of Sinopharm Healthcare Industry Co. Ltd. from June 2022 to September 2024. Mr. YANG is currently also the secretary of the Party Committee of the Company and the chairman and general manager (legal representative) of China National Traditional Chinese Medicine Co. Ltd. Mr. LI Hongjian, aged 38, has been appointed to the Board since 27 September 2024. Mr. LI graduated from Sun Yat-sen University with a bachelor degree majoring in business administration (human resources management) in July 2008 and completed MBA postgraduate study in Sun Yat-sen University in July 2014. Mr. LI has senior economist and management consultant certificates. Mr. LI was an assistant of human resource department of Foshan Water Industry Group Co. Ltd. () from July 2008 to September 2011; successively served as chief assistant and manager of human resource department of Guangzhou Southern Investment Group Co. Ltd. under China Southern Power Grid from September 2011 to November 2016; served as general manager of personnel administration of Guangzhou Electric Power Construction Co. Ltd. under China Southern Power Grid from November 2016 to March 2018; successively served as deputy director and director of human resource department of the Company and secretary of the third branch Party Committee of the headquarter of the Company from April 2018 to June 2021; successively served as interim deputy secretary of the Party Committee, interim secretary of the Discipline Inspection Commission (temporary position), interim secretary of the Discipline Inspection Commission, general manager of data operation center and general manager of strategy and data operation center of Chongqing Taiji Industry (Group) Co. Ltd. (listed on the Shanghai Stock Exchange, stock code: 600129) from June 2021 to September 2024; served as an executive director of Chongqing Medicines & Health Products Import & Export Co. Ltd. (currently known as Chongqing Taiji International Healthcare Industry Co. Ltd.) from August 2022 to September 2024. Mr. LI is currently also the deputy secretary of the Party Committee of the Company.

Announcement • Mar 23

+ 1 more update

China Traditional Chinese Medicine Holdings Co. Limited Announces Board Changes

China Traditional Chinese Medicine Holdings Co. Limited announced that the Board has received written resignation reports from Mr. CHENG Xueren ("Mr. CHENG") and Mr. YANG Wenming ("Mr. YANG"). As they are reaching the retirement age, Mr. CHENG has applied to resign as the president of the Company (i.e. the general manager), and to re-designate from an executive Director and the managing Director to a non-executive Director; and Mr. YANG has applied to resign as the vice president of the Company, and to re-designate from an executive Director to a non-executive Director. The Board resolved that Mr. CHENG and Mr. YANG shall cease to serve as members of the senior management of the Company, and shall be re-designated to non-executive Directors, with effect from 21 March 2024, and shall continue to serve as members of the nomination committee and strategic committee of the Board. The Board also resolved that Mr. CHEN Yinglong, an executive Director and the chairman of the Board, shall be appointed as the acting president (i.e. the general manager) with effect from 21 March 2024. Mr. CHEN will be responsible for the implementation of the important policies and development strategies approved by the Board and has direct management responsibility for the daily operations of the Group. The Board will maintain standardized operation in accordance with the laws and regulations to ensure the continued stability of the Company's operation. Mr. CHEN, aged 52, was appointed to the Board and served as the Chairman of the Board on 12 May 2022. Mr. CHEN graduated from Heilongjiang University with a bachelor degree of English majoring in English Literature in 1993 and completed the master course of Management Science and Engineering in School of Management of Harbin Institute of Technology in 1999. Mr. CHEN has the professional qualification of senior enterprise information manager and senior economist. Mr. CHEN was the business manager of the first business department of Harbin Metals and Minerals Import and Export Corporation from December 1993 to September 1994; the first representative of Harbin branch of Eisenberg Group United Development Co. Ltd. from September 1994 to October 1999; the general manager of Harbin Runhe Technology Development Co. Ltd. from October 1999 to April 2004; a director and general manager of Harbin Baida Pharmaceutical Co. Ltd. from April 2004 to November 2009; a manager of the raw material department and successively a manager of the safety and environmental protection department of China National Pharmaceutical Industry Company Limited from November 2009 to August 2010; the deputy general manager, general legal adviser and secretary of the board of directors of China Traditional Chinese Medicine Co. Ltd. (formerly known as China National Corp. of Traditional & Herbal Medicine) from August 2010 to December 2018. He served as a vice president of the Company from December 2018 to May 2020, during which he was also the standing committee member of the municipal committee and deputy mayor of Baishan City of Jilin Province. He has been director of public affairs department of China National Pharmaceutical Group Co. Ltd. from May 2020 to June 2022. Mr. CHEN is currently the secretary of the Party Committee of the Company (as the acting president (i.e. the general manager)), and the chairman of the board, general manager and provisional deputy Party secretary of the China Traditional Chinese Medicine Co. Ltd. Mr. CHENG, aged 60, was appointed to the Board on 25 March 2022. Mr. CHENG was graduated from Anhui Institute of Traditional Chinese Medicine (currently known as Anhui University of Traditional Chinese Medicine) with a bachelor degree in Traditional Chinese Medicine in 1985, and finished master course of Basic Theory of Integrated Chinese and Western Medicine in Guangzhou University of Chinese Medicine in 1992. Mr. CHENG has the professional qualifications of chief pharmacist and attending physician. Mr. CHENG was a physician of Anhui Chuzhou People's Hospital from July 1985 to August 1989; a doctor of Guangdong Second Hospital of Traditional Chinese Medicine from July 1992 to March 1993; a R&D director, a person in charge of quality, a deputy manager of production, the deputy manager of sale, chairman, general manager and secretary of Party committee of Guangdong Yifang Pharmaceutical Co. Ltd. from March 1993 to September 2021. In which, he was the vice director of Guangdong Institute of Traditional Chinese Medicine from March 1993 to May 2015, a vice president and president of the Company from December 2019 to March 2024. Mr. CHENG has been a director of Chongqing Taiji Industry (Group) Co. Ltd. since 6 May 2022, and held directorship in multiple subsidiaries of the Company. Mr. YANG, aged 60, was appointed to the Board on 24 December 2018. Mr. YANG graduated from Zhejiang University majoring in Biological and Medical Instruments and obtained a bachelor degree of Engineering in 1985. Mr. YANG also has the senior engineer professional qualification. He was previously a staff member of the quality standard department, a senior staff member, a principal staff member, the deputy department head of the external cooperation department, the assistant of general manager and the department head of the external cooperation department and the assistant of general manager of China National Medical Equipment Industry Corporation from August 1985 to March 1999 and the assistant of the department head of the Medical Equipment Administration Department and the deputy director of the Medical Equipment Products Examination and Registration Centre of the State Medicine Administrative Bureau of China from January 1997 to January 1998. He was previously an office manager, manager of the information department, manager of the discipline inspection and supervision office, manager of the audit department, deputy secretary of discipline inspection committee, vice president of labour union and the staff supervisor of China National Pharmaceutical Group Corporation, and deputy general manager, deputy secretary of the Party Committee and secretary of discipline inspection committee, president of labour union of China National Pharmaceutical Industry Company Limited from March 1999 to April 2017; the deputy secretary of the Party Committee, secretary of discipline inspection committee and president of labour union of Shanghai Shyndec Pharmaceutical Co. Ltd. from November 2016 to December 2018; the secretary of the Party Committee and vice president of the Company from December 2018 to March 2024. Mr. YANG has held directorship in multiple subsidiaries of the Company.

Pharmaceuticals earnings growth	15.8%
Revenue growth rate	4.3%
Future return on equity	4.38%
Analyst coverage	Low
Last updated	30 Mar 2026

Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	15,884	N/A	800	N/A	2
12/31/2027	14,994	651	741	717	2
12/31/2026	14,378	317	673	685	1
12/31/2025	14,745	-342	1,957	2,281	N/A
9/30/2025	15,166	-303	2,221	2,610	N/A
6/30/2025	15,588	-265	2,484	2,939	N/A
3/31/2025	16,049	-105	2,278	2,761	N/A
12/31/2024	16,510	54	2,071	2,583	N/A
9/30/2024	16,857	486	1,990	2,470	N/A
6/30/2024	17,204	917	1,908	2,357	N/A
3/31/2024	17,663	1,101	1,294	1,763	N/A
12/31/2023	18,122	1,285	680	1,169	N/A
9/30/2023	17,909	1,107	174	695	N/A
6/30/2023	17,696	930	-332	222	N/A
3/31/2023	16,000	847	117	657	N/A
12/31/2022	14,304	764	566	1,092	N/A
9/30/2022	15,560	1,091	512	1,119	N/A
6/30/2022	16,815	1,417	458	1,146	N/A
3/31/2022	17,934	1,675	188	971	N/A
12/31/2021	19,053	1,933	-81	796	N/A
9/30/2021	17,677	1,897	374	1,372	N/A
6/30/2021	16,300	1,861	829	1,948	N/A
3/31/2021	15,553	1,762	-73	1,088	N/A
12/31/2020	14,806	1,663	-975	228	N/A
9/30/2020	14,423	1,562	-334	723	N/A
6/30/2020	14,039	1,461	308	1,218	N/A
3/31/2020	14,180	1,525	477	1,401	N/A
12/31/2019	14,321	1,588	646	1,585	N/A
9/30/2019	13,528	1,563	N/A	1,341	N/A
6/30/2019	12,735	1,538	N/A	1,097	N/A
3/31/2019	11,997	1,488	N/A	1,144	N/A
12/31/2018	11,259	1,439	N/A	1,190	N/A
9/30/2018	10,579	1,386	N/A	1,103	N/A
6/30/2018	9,900	1,332	N/A	1,016	N/A
3/31/2018	9,119	1,251	N/A	1,126	N/A
12/31/2017	8,338	1,170	N/A	1,236	N/A
9/30/2017	7,785	1,123	N/A	419	N/A
6/30/2017	7,233	1,075	N/A	-397	N/A
3/31/2017	6,883	1,021	N/A	534	N/A
12/31/2016	6,533	967	N/A	1,465	N/A
9/30/2016	6,010	880	N/A	1,248	N/A
6/30/2016	5,487	794	N/A	1,031	N/A
3/31/2016	4,598	670	N/A	775	N/A
12/31/2015	3,709	546	N/A	519	N/A
9/30/2015	3,271	509	N/A	N/A	N/A
6/30/2015	2,833	471	N/A	397	N/A

Data	Last Updated (UTC time)
Company Analysis	2026/06/08 21:52
End of Day Share Price	2026/06/08 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Helena Qiu	CCB International Securities Limited
Yue-Kwong Lui	CGS International
Yanyin Zhu	China International Capital Corporation Limited

China Traditional Chinese Medicine Holdings Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025

China Traditional Chinese Medicine Holdings Co. Limited Provides Earnings Guidance for the Six Months Ended June 30, 2025

Consensus EPS estimates fall by 31%

China Traditional Chinese Medicine Holdings Co. Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023

Consensus EPS estimates fall by 18%

Recent updates

Full year 2025 earnings: EPS misses analyst expectations

China Traditional Chinese Medicine Holdings Co. Limited, Annual General Meeting, Jun 26, 2026

China Traditional Chinese Medicine Holdings Co. Limited(SEHK:570) dropped from Hang Seng China Affiliated Corporations Index

China Traditional Chinese Medicine Holdings Co. Limited to Report Fiscal Year 2025 Results on Mar 20, 2026

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025

First half 2025 earnings released: CN¥0.021 loss per share (vs CN¥0.042 profit in 1H 2024)

First half 2025 earnings released: CN¥0.021 loss per share (vs CN¥0.042 profit in 1H 2024)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2025 Results on Aug 29, 2025

China Traditional Chinese Medicine Holdings Co. Limited Provides Earnings Guidance for the Six Months Ended June 30, 2025

China Traditional Chinese Medicine Holdings Co. Limited Approves Special Dividend for the Year Ended 31 December 2024

Upcoming dividend of HK$0.086 per share

China Traditional Chinese Medicine Holdings Co. Limited Announces Adjustments to the Composition of Board Committees, Effective from 20 June 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

Full year 2024 earnings: EPS and revenues miss analyst expectations

China Traditional Chinese Medicine Holdings Co. Limited, Annual General Meeting, Jun 18, 2025

China Traditional Chinese Medicine Holdings Co. Limited to Report Fiscal Year 2024 Results on Mar 25, 2025

Less than half of directors are independent

China Traditional Chinese Medicine Holdings Co. Limited Announces Change of Non-Executive Directors

Sinopharm Common Wealth Company Limited cancelled the acquisition of 67.54% stake in China Traditional Chinese Medicine Holdings Co. Limited (SEHK:570) from China Asset Management Co. Ltd., China Asset Management (Hong Kong) Limited and others.

First half 2024 earnings released: EPS: CN¥0.042 (vs CN¥0.12 in 1H 2023)

China Traditional Chinese Medicine Holdings Co. Limited Announces Executive, Board and Committee Appointments

Consensus EPS estimates fall by 31%

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.042 (vs CN¥0.12 in 1H 2023)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 15%

China Traditional Chinese Medicine Holdings Co. Limited Announces Board Changes

China Traditional Chinese Medicine Holdings Co. Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 26%

New minor risk - Share price stability

Less than half of directors are independent

Investor sentiment improves as stock rises 15%

China Traditional Chinese Medicine Holdings Co. Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023

Investor sentiment deteriorates as stock falls 20%

China Traditional Chinese Medicine Holdings Co. Limited's (HKG:570) P/E Still Appears To Be Reasonable

Is China Traditional Chinese Medicine Holdings (HKG:570) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

First half 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.082 in 1H 2022)

China Traditional Chinese Medicine Holdings Co. Limited Announces Resignation of Kui Kaipin as Non-Executive Director, with Effect from August 29, 2023

Calculating The Intrinsic Value Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2023 Results on Aug 29, 2023

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023

China Traditional Chinese Medicine Holdings Co. Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.052 per share at 1.3% yield

Is China Traditional Chinese Medicine Holdings (HKG:570) Using Too Much Debt?

China Traditional Chinese Medicine Holdings Co. Limited Proposes Final Dividend for the Year Ended 31 December 2022

Consensus EPS estimates fall by 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

China Traditional Chinese Medicine Holdings Co. Limited Provides Earning Guidance for the Year Ended 31 December 2022

China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Analysts Are Reducing Their Forecasts For This Year

Investor sentiment improved over the past week

China Traditional Chinese Medicine Holdings Co. Limited Announces Management Changes

Less than half of directors are independent

Consensus forecasts updated

These 4 Measures Indicate That China Traditional Chinese Medicine Holdings (HKG:570) Is Using Debt Extensively

China Traditional Chinese Medicine Holdings Co. Limited Do Not Recommend the Payment of an Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.082 (vs CN¥0.18 in 1H 2021)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2022 Results on Aug 26, 2022

China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Analysts Just Cut Their EPS Forecasts Substantially

Consensus revenue estimates fall by 11%

Calculating The Fair Value Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

China Traditional Chinese Medicine Holdings Co. Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 29 July 2022

Upcoming dividend of HK$0.074 per share

China Traditional Chinese Medicine Holdings Co. Limited Recommends Final Dividend for the Year Ended 31 December 2021

Here's Why I Think China Traditional Chinese Medicine Holdings (HKG:570) Is An Interesting Stock